Oppenheimer Issues Positive Forecast for Guardian Pharmacy Services (NYSE:GRDN) Stock Price

Guardian Pharmacy Services (NYSE:GRDN) had its price objective increased by Oppenheimer from $35.00 to $38.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would suggest a potential upside of 9.70% from the stock’s previous close.

Several other equities research analysts have also weighed in on GRDN. Stephens increased their target price on Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Guardian Pharmacy Services in a report on Monday, December 29th. UBS Group reissued a “buy” rating on shares of Guardian Pharmacy Services in a research note on Thursday. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 17th. Finally, Truist Financial set a $38.00 price target on Guardian Pharmacy Services and gave the company a “buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Guardian Pharmacy Services currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Guardian Pharmacy Services Stock Up 3.4%

GRDN stock traded up $1.13 during midday trading on Thursday, reaching $34.64. The company had a trading volume of 336,457 shares, compared to its average volume of 240,330. The stock has a 50 day moving average price of $31.81 and a 200 day moving average price of $29.32. Guardian Pharmacy Services has a fifty-two week low of $18.52 and a fifty-two week high of $37.43. The firm has a market capitalization of $2.19 billion, a PE ratio of 54.98 and a beta of 0.86.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.10. The business had revenue of $397.62 million for the quarter, compared to analysts’ expectations of $390.04 million. Guardian Pharmacy Services had a return on equity of 30.29% and a net margin of 2.90%.The firm’s revenue was up 17.4% compared to the same quarter last year. Research analysts predict that Guardian Pharmacy Services will post 0.87 EPS for the current year.

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brown Advisory Inc. grew its position in Guardian Pharmacy Services by 5.0% during the 2nd quarter. Brown Advisory Inc. now owns 1,682,476 shares of the company’s stock worth $35,854,000 after purchasing an additional 79,652 shares in the last quarter. Valiant Capital Management L.P. grew its holdings in shares of Guardian Pharmacy Services by 15.8% during the fourth quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after buying an additional 167,741 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Guardian Pharmacy Services by 3.3% during the third quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock valued at $30,000,000 after buying an additional 36,072 shares in the last quarter. Franklin Resources Inc. raised its position in Guardian Pharmacy Services by 8.2% during the third quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock valued at $27,705,000 after buying an additional 80,033 shares during the period. Finally, Vanguard Group Inc. raised its position in Guardian Pharmacy Services by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock valued at $27,675,000 after buying an additional 88,296 shares during the period.

Guardian Pharmacy Services News Summary

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Reported Q4 results topped estimates — EPS and revenue beat consensus, with revenue up ~17% year-over-year and organic growth of ~12%; net margin and ROE improved year-over-year. Zacks: GRDN Q4 beats
• Positive Sentiment: Company raised 2026 adjusted-EBITDA guidance to $120M–$124M, citing strong cash flow and progress through the IRA transition — a direct driver of the improved sentiment. Seeking Alpha: guidance raise
• Positive Sentiment: Operational growth indicators were strong: residents served rose ~10% to ~205,000, supporting revenue momentum and scale benefits for LTC pharmacy operations. BusinessWire: Q4 results & metrics
• Neutral Sentiment: Management hosted an earnings call and released full call transcripts — useful for investors wanting color on IRA transition timing, margin drivers and cadence of cash flow but not an immediate price mover by itself. InsiderMonkey: Q4 call transcript
• Neutral Sentiment: Company updated FY‑2026 guidance items; some public summaries show revenue targets roughly in line with consensus, but EPS guidance reporting was unclear in early summaries — watch for clarified guidance in the official release and next updates. MarketBeat: Q4 release & press
• Negative Sentiment: Valuation and margin context: stock trades at a relatively high P/E (~55) and reported net margin (~2.9%), which leaves limited room for disappointment — slowing growth or missed guidance could push sentiment negative. MarketBeat: valuation data

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.